10X Genomics

Yahoo Finance • 7 months ago

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • 7 months ago

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with theNIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD)... Full story

Yahoo Finance • 8 months ago

Q3 2023 10X Genomics Inc Earnings Call

Participants Cassie Corneau; Manager of IR and Strategic Finance; 10x Genomics, Inc. Justin J. McAnear; CFO; 10x Genomics, Inc. Serge Saxonov; Co-Founder, CEO & Director; 10x Genomics, Inc. Daniel Anthony Arias; MD & Senior Analyst; St... Full story

Yahoo Finance • 8 months ago

10x Genomics to Present at the Stephens 25th Annual Conference

PLEASANTON, Calif., Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25th An... Full story

Yahoo Finance • 10 months ago

Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others

Researchers uncover mechanisms behind divergent responses to immune checkpoint blockade between primary and metastatic brain tumors PLEASANTON, Calif., Sept. 5, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cel... Full story

Yahoo Finance • last year

Why Shares of NanoString Technologies Are Falling Thursday

Shares of NanoString Technologies (NASDAQ: NSTG) were down more than 16% Thursday morning and were down as much as 28.3% earlier in the day after the life sciences company lost a patent ruling in Germany. NanoString makes instruments and s... Full story

Yahoo Finance • last year

10x Genomics, Inc. (NASDAQ:TXG) Is Expected To Breakeven In The Near Future

10x Genomics, Inc. (NASDAQ:TXG) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. 10x Genomics, Inc., a life science technology company, develops and sells instruments, consum... Full story

Yahoo Finance • 2 years ago

10x Genomics to Host Investor Day on December 8, 2022

PLEASANTON, Calif., Oct. 31, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will host an Investor Day on December 8, 2022 at the company's headquarters in Pleasanton, CA starting at 9:00 a.m. Pacific Time. The event wil... Full story

Yahoo Finance • 2 years ago

Pacific Biosciences' Tools Expansion Doesn't Guarantee Success

Recent announcements are likely better news for 10x Genomics and Twist Bioscience than for the DNA-sequencing pioneer. Continue reading... Full story

Yahoo Finance • 2 years ago

Billionaire Ken Griffin is Selling These 10 Stocks in 2022

In this article, we discuss the 10 stocks billionaire Ken Griffin is selling in 2022. If you want to skip our detailed analysis of Griffon’s investment philosophy, hedge fund returns, and history, go directly to Billionaire Ken Griffin is... Full story

Yahoo Finance • 2 years ago

10x Genomics Reports First Quarter 2022 Financial Results

Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif., May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022. 10x Genomics Logo (PRNewsfoto/10x G... Full story

Yahoo Finance • 2 years ago

Here’s Why You Must Consider Investing in 10x Genomics (TXG)

ClearBridge Investments, an investment management firm, published its “All Cap Growth Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge All Cap Growth Strategy underperformed its Russel... Full story